Adial CEO to Speak at Spring MicroCap Rodeo on June 6

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company, announced its participation in the Spring MicroCap Rodeo Conference, scheduled for June 6, 2024, in New York City. Cary Claiborne, the President and CEO of Adial, will deliver a presentation at 2:00 p.m. Eastern Time on that day. This presentation will be accessible via live webcast and can be found on the company's investor relations page on their website.

During the conference, Adial’s management will hold one-on-one meetings with approved investors. The Spring MicroCap Rodeo Conference is distinctive as it is organized by and for investors and money managers. The event will feature executive management teams from over 25 MicroCap companies across various industries, allowing investors to explore top stock ideas through presentations and individual meetings. The conference aims to provide insights into key value drivers and emerging trends for the latter half of 2024 and beyond. Additionally, industry guest speakers and networking opportunities will be available.

Adial Pharmaceuticals focuses on developing treatments for addiction and related disorders. The company's leading investigational drug, AD04, is a serotonin-3 receptor antagonist targeting Alcohol Use Disorder (AUD) in heavy drinkers. AD04 was recently studied in the ONWARD™ Phase 3 clinical trial, which showed promising results in reducing alcohol consumption among patients with specific genetic markers identified through Adial's companion diagnostic genetic test. Besides AUD, AD04 is thought to have potential applications in treating other addictions, including Opioid Use Disorder, gambling addiction, and obesity.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!